Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Aug;27(8):638-650.
doi: 10.1111/tbj.14262. Epub 2021 Jun 17.

Randomized controlled trial comparing magnetic marker localization (MaMaLoc) with wire-guided localization in the treatment of early-stage breast cancer

Gerson M Struik  1 , Bram Schermers  2   3 , Ingeborg Mares  1 , Harold E Lont  1 , Jennifer W Bradshaw  4 , Bernard Ten Haken  3 , Theo J M Ruers  2   3 , Jurgen E M Mourik  5 , Erwin Birnie  6   7 , Taco M A L Klem  1
Affiliations
Randomized Controlled Trial

Randomized controlled trial comparing magnetic marker localization (MaMaLoc) with wire-guided localization in the treatment of early-stage breast cancer

Gerson M Struik et al. Breast J. 2021 Aug.

Abstract

Wire-guided localization (WGL) is the standard of care in the surgical treatment of nonpalpable breast tumors. In this study, we compare the use of a new magnetic marker localization (MaMaLoc) technique to WGL in the treatment of early-stage breast cancer patients. Open-label, single-center, randomized controlled trial comparing MaMaLoc (intervention) to WGL (control) in women with early-stage breast cancer. Primary outcome was surgical usability measured using the System Usability Scale (SUS, 0-100 score). Secondary outcomes were patient reported, clinical, and pathological outcomes such as retrieval rate, operative time, resected specimen weight, margin status, and reoperation rate. Thirty-two patients were analyzed in the MaMaLoc group and 35 in the WGL group. Patient and tumor characteristics were comparable between groups. No in situ complications occurred. Retrieval rate was 100% in both groups. Surgical usability was higher for MaMaLoc: 70.2 ± 8.9 vs. 58.1 ± 9.1, p < 0.001. Patients reported higher overall satisfaction with MaMaLoc (median score 5/5) versus WGL (score 4/5), p < 0.001. The use of magnetic marker localization (MaMaLoc) for early-stage breast cancer is effective and has higher surgical usability than standard WGL.

Keywords: breast carcinoma; magnetism; nonradioactive; patient satisfaction; surgery; surgical usability; trial registration; tumor localization.

PubMed Disclaimer

References

REFERENCES

    1. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet (London, England). 2000;355(9217):1822. https://doi.org/10.1016/S0140-6736(00)02277-7
    1. SEER Database. Cancer stat facts: female breast cancer. Published 2017. Accessed October 8, 2017. https://seer.cancer.gov/statfacts/html/breast.html
    1. Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575. https://doi.org/10.1056/NEJMoa020128
    1. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232. https://doi.org/10.1056/NEJMoa020989
    1. Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC “boost vs. no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 2000;55(3):219-232. https://doi.org/10.1016/s0167-8140(00)00210-3

Publication types

LinkOut - more resources